Monoclonal antibody of 100 μg targeting CD274 for FCM, IHC.
| Product Specifications | |
| Application | FC, IHC |
| Reactivity | Human |
| Clonality | Monoclonal IgG2b |
| Host | Mouse |
| Immunogen | Recombinant human PD-L1 extracellular domain |
| Gene ID - Human | |
| Gene ID - Mouse | |
| Formulation | 100 μg IgG in 100 μl volume of PBS containing 50% glycerol, pH 7.2. No preservative iscontained. |
| Citations for Anti-CD274 (PD-L1) (Human) mAb (Clone: 27A2) – 9 Found |
| Bridges-Webb, C. General practitioners and over-servicing. The Medical Journal Of Australia. 1992;156(2):140-1. PubMed - Comments: Used in: IHC |
| Schuchmann, M; Meyer, R G; Distler, E; von Stebut, E; Kuball, J; Schnürer, E; Wölfel, T; Theobald, M; Konur, A; Gregor, S; Schreiner, O; Huber, C; Galle, P R; Otto, G; Herr, W. The programmed death (PD)-1/PD-ligand 1 pathway regulates graft-versus-host-reactive CD8 T cells after liver transplantation. American Journal Of Transplantation : Official Journal Of The American Society Of Transplantation And The American Society Of Transplant Surgeons. 2008;8(11):2434-44. PubMed - Comments: Used in: IHC |
| Hino, Ryosuke; Kabashima, Kenji; Kato, Yu; Yagi, Hiroaki; Nakamura, Motonobu; Honjo, Tasuku; Okazaki, Taku; Tokura, Yoshiki. Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer. 2010;116(7):1757-66. PubMed - Comments: Used in: IHC |
| Gadiot, Jules; Hooijkaas, Anna I; Kaiser, Andrew D M; van Tinteren, Harm; van Boven, Hester; Blank, Christian. Overall survival and PD-L1 expression in metastasized malignant melanoma. Cancer. 2011;117(10):2192-201. PubMed - Comments: Used in: IHC |
| Droeser, Raoul A; Hirt, Christian; Viehl, Carsten T; Frey, Daniel M; Nebiker, Christian; Huber, Xaver; Zlobec, Inti; Eppenberger-Castori, Serenella; Tzankov, Alexander; Rosso, Raffaele; Zuber, Markus; Muraro, Manuele Giuseppe; Amicarella, Francesca; Cremonesi, Eleonora; Heberer, Michael; Iezzi, Giandomenica; Lugli, Alessandro; Terracciano, Luigi; Sconocchia, Giuseppe; Oertli, Daniel; Spagnoli, Giulio C; Tornillo, Luigi. Clinical impact of programmed cell death ligand 1 expression in colorectal cancer. European Journal Of Cancer (Oxford, England : 1990). 2013;49(9):2233-42. PubMed - Comments: Used in: IHC |
| Hamanishi, Junzo; Mandai, Masaki; Ikeda, Takafumi; Minami, Manabu; Kawaguchi, Atsushi; Murayama, Toshinori; Kanai, Masashi; Mori, Yukiko; Matsumoto, Shigemi; Chikuma, Shunsuke; Matsumura, Noriomi; Abiko, Kaoru; Baba, Tsukasa; Yamaguchi, Ken; Ueda, Akihiko; Hosoe, Yuko; Morita, Satoshi; Yokode, Masayuki; Shimizu, Akira; Honjo, Tasuku; Konishi, Ikuo. Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology. 2015;33(34):4015-22. PubMed - Comments: Used in: IHC |
| Wu, X; Zhang, H; Xing, Q; Cui, J; Li, J; Li, Y; Tan, Y; Wang, S. PD-1(+) CD8(+) T cells are exhausted in tumours and functional in draining lymph nodes of colorectal cancer patients. British Journal Of Cancer. 2014;111(7):1391-9. PubMed - Comments: Used in: IHC |
| Goto, Wataru; Kashiwagi, Shinichiro; Asano, Yuka; Takada, Koji; Morisaki, Tamami; Fujita, Hisakazu; Takashima, Tsutomu; Ohsawa, Masahiko; Hirakawa, Kosei; Ohira, Masaichi. Eribulin Promotes Antitumor Immune Responses in Patients with Locally Advanced or Metastatic Breast Cancer. Anticancer Research. 2018;38(5):2929-2938. PubMed - Comments: Used in: IHC |
| Ito, Nozomi; Tsujimoto, Hironori; Horiguchi, Hiroyuki; Shimazaki, Hideyuki; Miyazaki, Hiromi; Saitoh, Daizoh; Kishi, Yoji; Ueno, Hideki. Clinical Significance of Programmed Death Ligand-1 Expression in Esophageal Squamous Cell Carcinoma. The Journal Of Surgical Research. 2020;251:321-328. PubMed - Comments: Used in: IHC |